Lenalidomide is effective against relapsed chronic lymphocytic leukemia (CLL). We report the first case of long-term molecular remission with continuous lenalidomide treatment in a young patient with CLL relapsed to multiple treatments. Minimal residual disease was assessed by nested polymerase chain reaction on bone marrow samples with patient-specific primers. A 20-yr-old patient with standard-risk CLL was treated with lenalidomide after multiple relapses and achieved a 4 yr long complete molecular response with minimal toxicities. Published biologic data support that lenalidomide induces an immune-mediated control of CLL, and our case suggests that long-term treatment with lenalidomide is effective at a molecular level in patients with relapsed CLL.
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia / F. Spina, F. Rezzonico, L. Farina, P. Corradini. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - 90:4(2013 Apr), pp. 340-344.
|Titolo:||Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia|
SPINA, FRANCESCO (Primo)
REZZONICO, FRANCESCA (Secondo)
FARINA, LUCIA (Penultimo)
CORRADINI, PAOLO (Ultimo)
|Parole Chiave:||Chronic lymphocytic leukemia; Lenalidomide; Long-term treatment; Minimal residual disease|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||apr-2013|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1111/ejh.12068|
|Appare nelle tipologie:||01 - Articolo su periodico|